These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 15170592)
1. Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules. Shih SR; Chen SJ; Hakimelahi GH; Liu HJ; Tseng CT; Shia KS Med Res Rev; 2004 Jul; 24(4):449-74. PubMed ID: 15170592 [TBL] [Abstract][Full Text] [Related]
2. The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases. Li C; Wang H; Shih SR; Chen TC; Li ML Curr Med Chem; 2007; 14(8):847-56. PubMed ID: 17430140 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Andries K; Dewindt B; Snoeks J; Willebrords R; van Eemeren K; Stokbroekx R; Janssen PA Antimicrob Agents Chemother; 1992 Jan; 36(1):100-7. PubMed ID: 1317142 [TBL] [Abstract][Full Text] [Related]
5. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site. Wald J; Pasin M; Richter M; Walther C; Mathai N; Kirchmair J; Makarov VA; Goessweiner-Mohr N; Marlovits TC; Zanella I; Real-Hohn A; Verdaguer N; Blaas D; Schmidtke M Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19109-19115. PubMed ID: 31462495 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses. Meng B; Lan K; Xie J; Lerner RA; Wilson IA; Yang B Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13499-13508. PubMed ID: 32467165 [TBL] [Abstract][Full Text] [Related]
7. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Binford SL; Maldonado F; Brothers MA; Weady PT; Zalman LS; Meador JW; Matthews DA; Patick AK Antimicrob Agents Chemother; 2005 Feb; 49(2):619-26. PubMed ID: 15673742 [TBL] [Abstract][Full Text] [Related]
8. Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Egorova A; Ekins S; Schmidtke M; Makarov V Eur J Med Chem; 2019 Sep; 178():606-622. PubMed ID: 31226653 [TBL] [Abstract][Full Text] [Related]
9. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Bauer L; Lyoo H; van der Schaar HM; Strating JR; van Kuppeveld FJ Curr Opin Virol; 2017 Jun; 24():1-8. PubMed ID: 28411509 [TBL] [Abstract][Full Text] [Related]
10. Rhinovirus Inhibitors: Including a New Target, the Viral RNA. Real-Hohn A; Blaas D Viruses; 2021 Sep; 13(9):. PubMed ID: 34578365 [TBL] [Abstract][Full Text] [Related]
11. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887 [TBL] [Abstract][Full Text] [Related]